A CAR-T response prediction model for r/r B-NHL patients based on a T cell subset nomogram.

ABSTRACT:

Background

Chimeric antigen receptor (CAR) T cells for refractory or relapsed (r/r) B cell no-Hodgkin lymphoma (NHL) patients have shown promising clinical effectiveness. However, the factors impacting the clinical response of CAR-T therapy have not been fully elucidated. We here investigate the independent influencing factors of the efficacy of CD19 CAR-T cell infusion in the treatment of r/r B-NHL and to establish an early prediction model.

Methods

A total of 43 r/r B-NHL patients were enrolled in this retrospective study. The patients' general data were recorded, and the primary endpoint is the patients' treatment response. The independent factors of complete remission (CR) and partial remission (PR) were investigated by univariate and binary logistic regression analysis,

SUBMITTER: Zhang X 

PROVIDER: S-EPMC10821965 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature